Inclusion Criteria:

          -  Symptomatic multiple myeloma by International Myeloma Working Group (IMWG) criteria
             according to the most recent updated version (International Myeloma Workshop [IMW]
             meeting in Paris 2011)

          -  Must have received at least 3 of the following classes of anti-myeloma agents either
             alone or in combination: glucocorticoids, immunomodulatory drugs including
             thalidomide, proteasome inhibitors, alkylating chemotherapy, or anthracyclines

          -  Must meet any of these criteria for high risk disease:

               -  Relapse or progressive disease according to uniform response criteria within 2
                  years after starting first-line therapy or within 2 years after autologous stem
                  cell transplant

               -  Failure to achieve partial response (PR) within 6 months of staring first-line
                  therapy

               -  Presence of high risk cytogenetic features (t(14;16), t(14;20), deletion 17p)

               -  Chromosome 14 translocations other than to chromosome 11

               -  Chromosome 1p deletion and 1q amplification

               -  MyPRS gene expression score equal or higher than 45.2

               -  High risk 70 gene expression profile (MyPRS GEP70TM)

               -  Any other high risk genetic profile that is determined by future IMWG consensus
                  or by internal myeloma panel consensus; for the latter, any additional criteria
                  will be submitted as an addendum

               -  Diagnosis with multiple myeloma between the ages of 18-50

          -  Must have achieved at least a minor response to any previous regimen according to
             adapted European Group for Blood and Marrow Transplantation (EBMT) criteria

          -  Must have suitable matched sibling or matched unrelated donor for stem cell source

          -  Must be transplant-eligible per institution guidelines

          -  Must have estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal
             Disease (MDRD) formula or Cockroft-Gault formula of 50mL/min or higher

          -  All study participants must be registered into the mandatory Revlimid REMS® program,
             and be willing and able to comply with the requirements of Revlimid REMS®

          -  Females of childbearing potential must have negative serum or urine pregnancy test and
             use acceptable birth control methods

          -  Able to take aspirin daily as prophylactic anticoagulation (patients intolerant to
             acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)

        Exclusion Criteria:

        Participants must not:

          -  Have known hypersensitivity to thalidomide or lenalidomide

          -  Have progressive disease at the time of transplant

          -  Uncontrolled concurrent significant medical or psychological co-morbidity

          -  Grade 3 peripheral neuropathy

          -  Known seropositive for or active viral infection with human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are
             seropositive because of hepatitis B virus vaccine are eligible

          -  Be females who are pregnant

          -  Recent (within 3 years) history of other malignancies, excluding basal cell carcinoma
             or squamous cell carcinoma of the skin

          -  Be currently enrolled in another investigational treatment protocol